European Pharmacopoeia -ph. Eur.- Monograph Tablets -0478- [2025]

Use Ph. Eur. Monograph 0478 as your minimum quality standard for uncoated and film-coated immediate-release tablets. For regulatory submissions (e.g., CEP, DMF, or marketing authorization in Europe), you must comply with it. However, to achieve robust product quality, supplement it with:

A significant portion of the monograph is dedicated to the . Many tablets bear break marks (or break-marks) to allow them to be split, either to ease intake or to deliver fractional doses. However, the monograph makes a crucial distinction:

: This ensures that each tablet contains the correct amount of active substance. This is typically measured through Uniformity of Mass (2.9.5) Uniformity of Content (2.9.6) Dissolution (2.9.3)

serves as the authoritative, legally binding framework dictating the production, testing, and quality standards for oral tablets across Europe. Managed by the European Directorate for the Quality of Medicines & HealthCare (EDQM) , this general dosage form monograph establishes the compliance floor that pharmaceutical manufacturers must meet to secure and retain marketing authorizations. 1. Scope and Core Definition European Pharmacopoeia -ph. Eur.- Monograph Tablets -0478-

Manufacturers must implement measures to ensure tablets possess sufficient mechanical strength to withstand handling. Standardized testing includes:

By understanding and adhering to the standards of Monograph 0478, manufacturers can produce safe, effective, and reliable products that meet the high expectations of regulators and, most importantly, the needs of patients worldwide.

Following Ph. Eur. standards is legally binding for marketing medicines in signatory states. It provides the scientific basis for quality control throughout a product's life cycle—from development to final distribution. Use Ph

, is a general monograph that describes the individual and general quality standards for this specific dosage form. It covers everything from the physical definition—usually straight, circular solid cylinders with flat or convex surfaces—to the complex chemical and mechanical tests required for release. Key Quality Requirements

| Requirement | Details | | :--- | :--- | | | Tablets must be robust enough for handling and subsequent processing. This is assessed through tests like Friability of uncoated tablets (2.9.7) and Resistance to crushing of tablets (2.9.8) . | | Uniformity of Subdivided Parts (for Scored Tablets) | For tablets with break-marks used to split doses, the manufacturer must demonstrate that the subdivided parts are uniform. The test involves breaking 30 tablets, weighing one half from each, and ensuring no more than one mass falls outside 85-115% of the average mass. | | Microbiological Quality | Suitable measures must be taken to ensure microbiological quality throughout the lifecycle, in line with general chapter 5.1.4. |

: Tablets designed to disperse rapidly in the mouth or dissolve in water before administration. 3. Production and Quality Control Requirements For regulatory submissions (e

The monograph establishes distinct classifications for oral tablets to address diverse therapeutic targets and drug release profiles:

Although friability is sometimes considered a "secondary" test, Monograph 0478 references it explicitly for uncoated tablets.

The legal status of the Ph. Eur. is defined by the Convention on the Elaboration of a European Pharmacopoeia (1964). In EU law, any medicine seeking a Marketing Authorization (via the centralized, decentralized, or national procedure) must comply with the relevant Ph. Eur. monographs. Thus, Monograph 0478 is not a guideline but a . A batch of tablets failing the dissolution or uniformity test is considered adulterated and cannot be released to the market.